Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
